Korsana Biosciences, Inc. earnings releases KRSA

Annual Quarterly

Korsana Biosciences, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$3.19. It usually reports 36–73 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 11, 2027.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–73 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Nov 5, 2026
36 days after quarter end
Q3 FY2026
ended Sep 30, 2026
—
-46
-113.7%
-3.19
+91.9%
Sep 11, 2026
73 days after quarter end
Q2 FY2026
ended Jun 30, 2026
0
-100.0%
-17
-11321.1%
-0.41
-272.7%
May 12, 2023
42 days after quarter end
—
ended Mar 31, 2023
—
—
—
Aug 9, 2022
40 days after quarter end
—
ended Jun 30, 2022
—
—
—
May 4, 2022
34 days after quarter end
—
ended Mar 31, 2022
—
—
—
Feb 24, 2022
55 days after quarter end
—
ended Dec 31, 2021
—
—
—
Nov 9, 2021
40 days after quarter end
—
ended Sep 30, 2021
—
—
—
Jul 29, 2021
29 days after quarter end
—
ended Jun 30, 2021
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KRSA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
MA
Headquarters
Waltham, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1755237
Former names
Cyclerion Therapeutics, Inc. (until Aug 27, 2026)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.